Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

95.10 +0.47 (+0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Blueprint Medicines Corp

< Previous 1 2 3 4 5 6 Next >
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities. 
Via Benzinga
Key Takeaways From Blueprint Medicines Analyst Ratings
Via Benzinga
Analyst Ratings For Blueprint Medicines
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
15 Analysts Have This To Say About Blueprint Medicines
Via Benzinga
Expert Ratings For Blueprint Medicines
Via Benzinga
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Unveiling 18 Analyst Insights On Blueprint Medicines
Via Benzinga
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024
BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Via Benzinga
Decoding 6 Analyst Evaluations For Blueprint Medicines
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
(BPMC) - Analyzing Blueprint Medicines's Short Interest
Via Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
The company reported better-than-expected sales of its rare-disease drug, but there's one drawback in its report. 
Via Investor's Business Daily
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Blueprint Medicines's Earnings Outlook
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
Via Benzinga
Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
Via Benzinga
Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. 
Via Talk Markets
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
The Latest Analyst Ratings for Blueprint Medicines
Via Benzinga
Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Why Blueprint Medicines Stock Soared Today
The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.